Entropy Technologies LP Invests $259,000 in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Entropy Technologies LP acquired a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 32,757 shares of the company's stock, valued at approximately $259,000.

Several other institutional investors have also added to or reduced their stakes in AMRX. JPMorgan Chase & Co. boosted its holdings in shares of Amneal Pharmaceuticals by 149.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company's stock valued at $10,792,000 after purchasing an additional 777,568 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in Amneal Pharmaceuticals by 114.1% in the third quarter. Assenagon Asset Management S.A. now owns 1,204,994 shares of the company's stock valued at $10,026,000 after buying an additional 642,065 shares in the last quarter. Geode Capital Management LLC boosted its stake in Amneal Pharmaceuticals by 11.1% in the third quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company's stock valued at $31,511,000 after buying an additional 378,136 shares in the last quarter. Polar Asset Management Partners Inc. grew its position in Amneal Pharmaceuticals by 122.5% in the third quarter. Polar Asset Management Partners Inc. now owns 393,000 shares of the company's stock valued at $3,270,000 after acquiring an additional 216,400 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Amneal Pharmaceuticals by 16.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,404,883 shares of the company's stock worth $11,689,000 after acquiring an additional 202,863 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Stock Performance

Shares of Amneal Pharmaceuticals stock traded down $0.18 on Monday, hitting $7.73. The stock had a trading volume of 484,881 shares, compared to its average volume of 1,200,624. The stock has a 50 day moving average of $8.06 and a 200 day moving average of $8.26. Amneal Pharmaceuticals, Inc. has a twelve month low of $5.01 and a twelve month high of $9.48. The firm has a market capitalization of $2.40 billion, a P/E ratio of -11.37 and a beta of 1.10.

Analyst Ratings Changes

AMRX has been the subject of a number of research analyst reports. StockNews.com cut shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Thursday, December 19th. Piper Sandler boosted their target price on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an "overweight" rating in a research note on Monday, November 11th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $10.00.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 17,410 shares of Amneal Pharmaceuticals stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $8.01, for a total transaction of $139,454.10. Following the transaction, the director now directly owns 2,031,476 shares of the company's stock, valued at approximately $16,272,122.76. The trade was a 0.85 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last ninety days, insiders sold 160,000 shares of company stock worth $1,292,000. 26.56% of the stock is currently owned by company insiders.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.